Paradigm Biopharmaceuticals Ltd (PAR) listed on the ASX in August 2015. We focus on repurposing pentosan polysulphate sodium (PPS) for the treatment of conditions that begin with and are sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties. Our lead clinical indications include treating bone marrow edema (BME), an increasingly recognised pathological ...
Paradigm Biopharmaceuticals Ltd (PAR) listed on the ASX in August 2015. We focus on repurposing pentosan polysulphate sodium (PPS) for the treatment of conditions that begin with and are sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties. Our lead clinical indications include treating bone marrow edema (BME), an increasingly recognised pathological change in bone and a significant contributor to pain and symptoms in Osteoarthritis and acute joint injury; and the treatment of joint function, mobility and pain in patients with mucopolysaccharidoses (MPS).
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.